熱門資訊> 正文
Interse ENT报告Propel鼻窦植入物的真实证据研究的积极数据
2022-01-25 21:07
08:02 AM EST, 01/25/2022 (MT Newswires) -- Intersect ENT (XENT) reported positive results Tuesday from a study of its Propel sinus implants using real-world evidence data from adult patients with chronic rhinosinusitis who underwent endoscopic sinus surgery.
The medical device company said the results show that patients receiving Propel sinus implants after sinus surgery had lower healthcare resource utilization over an 18-month postoperative period compared with patients who did not receive an implant.
"These results clearly demonstrate a positive impact of the Propel sinus implants," said President and Chief Executive Officer Thomas West.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
